Certain Blood Separation and Cell Preparation Devices; Notice of Commission Determination Not To Review an Initial Determination Terminating the Investigation Based on the Withdrawal of the Complaint; Termination of Investigation, 6970-6971 [2020-02337]
Download as PDF
<![CDATA[
6970
Federal Register / Vol. 85, No. 25 / Thursday, February 6, 2020 / Notices
the opinion of the Office of General
Counsel that the Coquille Tribe of
Oregon’s Class III gaming ordinance is
compliant with the requirements of
IGRA and NIGC regulations. A copy of
the ordinance and approval letter can be
found on the NIGC’s website
(www.nigc.gov) under General Counsel,
Gaming Ordinances. A copy of the
approved Class III gaming ordinance
will also be made available upon
request. Requests can be made in
writing to the Office of General Counsel,
National Indian Gaming Commission,
Attn: Frances Fragua, 1849 C Street NW,
MS #1621, Washington, DC 20240.
National Indian Gaming Commission.
Dated: January 31, 2020.
Michael Hoenig,
General Counsel.
[FR Doc. 2020–02353 Filed 2–5–20; 8:45 am]
BILLING CODE 7565–01–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1024]
Certain Integrated Circuits With
Voltage Regulators and Products
Containing Same; Notice of
Commission Determination Not To
Review an Initial Determination
Terminating the Investigation for Good
Cause; Termination of Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission (‘‘Commission’’) has
determined not to review an initial
determination (‘‘ID’’) (Order No. 59) that
grants a joint motion to terminate this
investigation for good cause. This
investigation is terminated.
FOR FURTHER INFORMATION CONTACT: Ron
Traud, Office of the General Counsel,
U.S. International Trade Commission,
500 E Street SW, Washington, DC
20436, telephone 202–205–3427. Copies
of non-confidential documents filed in
connection with this investigation are or
will be available for inspection during
official business hours (8:45 a.m. to 5:15
p.m.) in the Office of the Secretary, U.S.
International Trade Commission, 500 E
Street SW, Washington, DC 20436,
telephone 202–205–2000. General
information concerning the Commission
may also be obtained by accessing its
internet server at https://www.usitc.gov.
The public record for this investigation
may be viewed on the Commission’s
electronic docket (‘‘EDIS’’) at https://
edis.usitc.gov. Hearing-impaired
lotter on DSKBCFDHB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:54 Feb 05, 2020
Jkt 250001
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal, telephone 202–205–1810.
SUPPLEMENTARY INFORMATION: On
October 18, 2016, the Commission
instituted this investigation based on a
complaint filed by R2 Semiconductor,
Inc. of Sunnyvale, California. 81 FR
71764 (Oct. 18, 2016). The complaint
alleges violations of section 337 of the
Tariff Act of 1930, as amended, 19
U.S.C. 1337 (‘‘section 337’’) based upon
the importation into the United States,
the sale for importation, or the sale
within the United States after
importation of certain integrated circuits
with voltage regulators and products
containing the same by reason of
infringement of certain claims of U.S.
Patent No. 8,233,250 (‘‘the ’250 patent’’).
Id. The Commission’s notice of
investigation named as respondents
Intel Corporation of Santa Clara,
California; Intel Ireland Ltd. of Leixlip,
Ireland; Intel Products Vietnam Co., Ltd.
of Ho Chi Minh City, Vietnam; Intel
Israel 74 Ltd. of Haifa, Israel; Intel
Malaysia Sdn. Berhad of Penang,
Malaysia; Intel China, Ltd. of Beijing,
China; Dell, Inc. of Round Rock, Texas;
Dell Technologies Inc. of Round Rock,
Texas; HP Inc. of Palo Alto, California;
and Hewlett Packard Enterprise Co. of
Palo Alto, California (collectively,
‘‘Respondents’’). Id. The Office of Unfair
Import Investigations (‘‘OUII’’) is
participating in this investigation. Id.
On July 31, 2018, the Patent Trial and
Appeal Board (‘‘PTAB’’) issued final
written decisions in inter partes review
proceedings, finding all asserted claims
of the ’250 patent to be invalid. On
August 16, 2018, Respondents filed an
unopposed motion to stay this
investigation pending appellate review
of those decisions by the Federal
Circuit. On August 31, 2018, the
presiding administrative law judge
(‘‘ALJ’’) granted that motion. Order No.
55 (Aug. 31, 2018).
On December 23, 2019, R2 and
Respondents filed a joint motion to
terminate this investigation in its
entirety for good cause in light of the
Federal Circuit’s November 13, 2019
decision affirming the PTAB’s decision
finding all asserted claims of the ’250
patent unpatentable. OUII did not
oppose the motion.
On January 10, 2020, the ALJ issued
the subject ID (Order No. 59), which
grants the motion. The ALJ found that
the motion complies with Commission
Rule 210.21(a) and that no extraordinary
circumstances prohibit termination of
the investigation. No petitions for
review were filed.
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
The Commission has determined not
to review the subject ID. This
investigation is terminated.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
By order of the Commission.
Issued: January 31, 2020.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2020–02292 Filed 2–5–20; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1147]
Certain Blood Separation and Cell
Preparation Devices; Notice of
Commission Determination Not To
Review an Initial Determination
Terminating the Investigation Based
on the Withdrawal of the Complaint;
Termination of Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission (‘‘Commission’’) has
determined not to review an initial
determination (‘‘ID’’) (Order No. 17) that
grants the complainant’s motion to
terminate this investigation based on the
withdrawal of the complaint. This
investigation is terminated.
FOR FURTHER INFORMATION CONTACT: Ron
Traud, Office of the General Counsel,
U.S. International Trade Commission,
500 E Street SW, Washington, DC
20436, telephone 202–205–3427. Copies
of non-confidential documents filed in
connection with this investigation are or
will be available for inspection during
official business hours (8:45 a.m. to 5:15
p.m.) in the Office of the Secretary, U.S.
International Trade Commission, 500 E
Street SW, Washington, DC 20436,
telephone 202–205–2000. General
information concerning the Commission
may also be obtained by accessing its
internet server at https://www.usitc.gov.
The public record for this investigation
may be viewed on the Commission’s
electronic docket (‘‘EDIS’’) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal, telephone 202–205–1810.
SUMMARY:
E:\FR\FM\06FEN1.SGM
06FEN1
Federal Register / Vol. 85, No. 25 / Thursday, February 6, 2020 / Notices
The
Commission instituted this investigation
on March 12, 2019, based on a
complaint filed by RegenLab USA LLC
of New York, New York (‘‘RegenLab’’).
84 FR 8891 (Mar. 12, 2019). The
complaint, as amended, alleges
violations of section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C. 1337
(‘‘section 337’’), based upon the
importation into the United States, the
sale for importation, and the sale within
the United States after importation of
certain blood separation and cell
preparation devices by reason of
infringement of certain claims of U.S.
Patent No. 10,064,894. Id. The amended
complaint further alleges that an
industry in the United States exists as
required by section 337. Id. The notice
of investigation named as respondents
Estar Technologies, Ltd. of Holon, Israel,
and Eclipse MedCorp, LLC of The
Colony, Texas (collectively,
‘‘Respondents’’). Id. The Office of Unfair
Import Investigations (‘‘OUII’’) was
named as a party to the investigation. Id.
On November 13, 2019, RegenLab
filed a motion to terminate the
investigation in its entirety based on the
withdrawal of the complaint. On
November 15, 2019, Respondents filed a
response stating that they did not
oppose the motion to terminate, on the
condition that an order to show cause
issue regarding whether RegenLab and
its previous counsel should not be
sanctioned. On November 22, 2019,
Respondents filed a motion seeking that
show cause order. On November 25,
2019, OUII filed a response supporting
the motion to terminate the
investigation.
On December 20, 2019, the presiding
administrative law judge (‘‘ALJ’’) issued
Order No. 16, which denied
Respondents’ motion for the show cause
order.
Also on December 20, 2019, the ALJ
issued Order No. 17, the subject ID,
granting pursuant to 19 CFR 210.21(a)
RegenLab’s motion to terminate the
investigation. The ID finds that
RegenLab’s motion complies with the
Commission’s Rules. No petitions for
review were filed.
The Commission has determined not
to review the subject ID. However, the
Commission notes that RegenLab filed
its motion to terminate six days before
the hearing was scheduled to begin,
after extensive proceedings, including
discovery, had occurred before the ALJ.
As a general matter, the Commission
notes that withdrawal of a complaint at
such a late stage of the investigation
raises questions about what effect, if
any, termination would have on a future
complaint that might be filed based on
lotter on DSKBCFDHB2PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
19:54 Feb 05, 2020
Jkt 250001
the same or similar alleged violations of
section 337 by the same respondents,
and how the record from the terminated
investigation may be used in such a
future investigation. This investigation
is terminated.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
By order of the Commission.
Issued: January 31, 2020.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2020–02337 Filed 2–5–20; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1089]
Certain Memory Modules and
Components Thereof; Commission
Determination To Review in Part a
Final Initial Determination Finding a
Violation of Section 337; Schedule for
Filing Written Submissions on the
Issues Under Review and on Remedy,
the Public Interest, and Bonding;
Extension of the Target Date
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission has determined to review
in part a final initial determination
(‘‘ID’’) issued by the presiding
administrative law judge (‘‘ALJ’’),
finding a violation of section 337 of the
Tariff Act of 1930. The Commission
requests briefing from the parties on
certain issues under review, as
indicated in this notice. The
Commission also requests briefing from
the parties and interested persons on the
issues of remedy, the public interest,
and bonding. The Commission has also
determined to extend the target date for
the completion of the above-captioned
investigation to April 7, 2020.
FOR FURTHER INFORMATION CONTACT:
Robert Needham, Office of the General
Counsel, U.S. International Trade
Commission, 500 E Street SW,
Washington, DC 20436, telephone (202)
708–5468. Copies of non-confidential
documents filed in connection with this
investigation are or will be available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
SUMMARY:
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
6971
International Trade Commission, 500 E
Street SW, Washington, DC 20436,
telephone (202) 205–2000. General
information concerning the Commission
may also be obtained by accessing its
internet server (https://www.usitc.gov).
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted this investigation
on December 4, 2017, based on a
complaint filed by Netlist, Inc. of Irvine,
California (‘‘Netlist’’). 82 FR 57290–91.
The complaint, as supplemented,
alleges violations of section 337 of the
Tariff Act of 1930, as amended, 19
U.S.C. 1337, in the importation into the
United States, the sale for importation,
and the sale within the United States
after importation of certain memory
modules and components thereof that
infringe claims 1–8, 10, 12, 14, 16–22,
24, 25, 27, 29–35, 38, 43–45, 47, 48, 50,
52, and 58 of U.S. Patent No. 9,606,907
(‘‘the ’907 patent’’) and claims 1–5, 7–
15, 17–25, 27, and 29 of U.S. Patent No.
9,535,623 (‘‘the ’623 patent’’). Id. The
Commission’s notice of investigation
named as respondents SK hynix Inc. of
the Republic of Korea; SK hynix
America Inc. of San Jose, California; and
SK hynix memory solutions Inc. of San
Jose, California (together, ‘‘SK hynix’’).
Id. at 57291. The Office of Unfair Import
Investigations (‘‘OUII’’) is also
participating in this investigation. Id.
The Commission subsequently
terminated the investigation with
respect to claims 16–22, 24, 25, 27, 29–
35, 38, 43–45, 47, 48, 50, 52, and 58 of
the ’907 patent and claims 12–15, 17–
25, 27, and 29 of the ’623 patent based
on Netlist’s partial withdrawal of its
complaint. See Order. No. 12 (Mar. 19,
2018), not reviewed, Notice (Apr. 5,
2019); Order. No. 19 (Sept. 25, 2018),
not reviewed, Notice (Oct. 15, 2018);
Order. No. 27 (Dec. 6, 2018), not
reviewed, Notice (Dec. 21, 2018).
Accordingly, at the time of the Final ID,
the remaining asserted claims were
claims 1–8, 10, 12, 14, and 15 of the
’907 patent and claims 1–5 and 7–11 of
the ’623 patent.
On October 19, 2019, the ALJ issued
a final initial determination (‘‘Final ID’’)
finding a violation of section 337 with
respect to claims 6 and 12 of the ’907
patent. Final ID at 164–65. The ALJ
found that Netlist showed that SK hynix
infringes claims 1–8, 10, 12, 14, and 15
of the ’907 patent, but failed to show
E:\FR\FM\06FEN1.SGM
06FEN1
]]>Agencies
[Federal Register Volume 85, Number 25 (Thursday, February 6, 2020)]
[Notices]
[Pages 6970-6971]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-02337]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 337-TA-1147]
Certain Blood Separation and Cell Preparation Devices; Notice of
Commission Determination Not To Review an Initial Determination
Terminating the Investigation Based on the Withdrawal of the Complaint;
Termination of Investigation
AGENCY: U.S. International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the U.S. International Trade
Commission (``Commission'') has determined not to review an initial
determination (``ID'') (Order No. 17) that grants the complainant's
motion to terminate this investigation based on the withdrawal of the
complaint. This investigation is terminated.
FOR FURTHER INFORMATION CONTACT: Ron Traud, Office of the General
Counsel, U.S. International Trade Commission, 500 E Street SW,
Washington, DC 20436, telephone 202-205-3427. Copies of non-
confidential documents filed in connection with this investigation are
or will be available for inspection during official business hours
(8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S.
International Trade Commission, 500 E Street SW, Washington, DC 20436,
telephone 202-205-2000. General information concerning the Commission
may also be obtained by accessing its internet server at https://www.usitc.gov. The public record for this investigation may be viewed
on the Commission's electronic docket (``EDIS'') at https://edis.usitc.gov. Hearing-impaired persons are advised that information
on this matter can be obtained by contacting the Commission's TDD
terminal, telephone 202-205-1810.
[[Page 6971]]
SUPPLEMENTARY INFORMATION: The Commission instituted this investigation
on March 12, 2019, based on a complaint filed by RegenLab USA LLC of
New York, New York (``RegenLab''). 84 FR 8891 (Mar. 12, 2019). The
complaint, as amended, alleges violations of section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C. 1337 (``section 337''), based upon
the importation into the United States, the sale for importation, and
the sale within the United States after importation of certain blood
separation and cell preparation devices by reason of infringement of
certain claims of U.S. Patent No. 10,064,894. Id. The amended complaint
further alleges that an industry in the United States exists as
required by section 337. Id. The notice of investigation named as
respondents Estar Technologies, Ltd. of Holon, Israel, and Eclipse
MedCorp, LLC of The Colony, Texas (collectively, ``Respondents''). Id.
The Office of Unfair Import Investigations (``OUII'') was named as a
party to the investigation. Id.
On November 13, 2019, RegenLab filed a motion to terminate the
investigation in its entirety based on the withdrawal of the complaint.
On November 15, 2019, Respondents filed a response stating that they
did not oppose the motion to terminate, on the condition that an order
to show cause issue regarding whether RegenLab and its previous counsel
should not be sanctioned. On November 22, 2019, Respondents filed a
motion seeking that show cause order. On November 25, 2019, OUII filed
a response supporting the motion to terminate the investigation.
On December 20, 2019, the presiding administrative law judge
(``ALJ'') issued Order No. 16, which denied Respondents' motion for the
show cause order.
Also on December 20, 2019, the ALJ issued Order No. 17, the subject
ID, granting pursuant to 19 CFR 210.21(a) RegenLab's motion to
terminate the investigation. The ID finds that RegenLab's motion
complies with the Commission's Rules. No petitions for review were
filed.
The Commission has determined not to review the subject ID.
However, the Commission notes that RegenLab filed its motion to
terminate six days before the hearing was scheduled to begin, after
extensive proceedings, including discovery, had occurred before the
ALJ. As a general matter, the Commission notes that withdrawal of a
complaint at such a late stage of the investigation raises questions
about what effect, if any, termination would have on a future complaint
that might be filed based on the same or similar alleged violations of
section 337 by the same respondents, and how the record from the
terminated investigation may be used in such a future investigation.
This investigation is terminated.
The authority for the Commission's determination is contained in
section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and
in part 210 of the Commission's Rules of Practice and Procedure (19 CFR
part 210).
By order of the Commission.
Issued: January 31, 2020.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2020-02337 Filed 2-5-20; 8:45 am]
BILLING CODE 7020-02-P
